Symic Bio to Present at Upcoming Conferences
- Chief Executive Officer Ken Horne to present at the BIO CEO & Investor Conference 2017 and the Cowen Health Care Conference -
SAN FRANCISCO, Feb. 6, 2017 /PRNewswire/ -- Symic Bio, a clinical-stage biotech company that is developing a new category of therapeutics focused on matrix biology, today announced that Ken Horne, Chief Executive Officer, will present at the following upcoming events:
BIO CEO & Investor Conference
Date: Monday, Feb. 13, 2017
Time: 9:30 a.m. EST
Location: Waldorf Astoria, New York
Cowen and Company Health Care Conference
Date: Monday, March 6, 2017
Time: 3:30 p.m. EST
Location: Boston Marriott Copley Place
About Symic Bio
Symic Bio is a clinical-stage biotech company that is developing a new category of therapeutics that are matrix regulators. Matrix regulators target the non-cellular component of tissue and enable new ways to affect disease and healing processes. Matrix regulators have potential applications in a wide variety of indications. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.
For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
Investor Contacts
Gitanjali Jain Ogawa
The Trout Group
(646) 378-2949
[email protected]
Media Contacts
David Schull or Rich Allan
Russo Partners, LLC
(212) 845-4271
(646) 942-5588
[email protected]
[email protected]
SOURCE Symic Bio
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article